Business Wire

BRIDGETOWER-CAPITAL

23.3.2022 17:05:05 CET | Business Wire | Press release

Share
BridgeTower Capital Teams with Securitize and Chainlink to Expand Offerings in Staking, DeFi and Permissioned Markets on Avalanche

BridgeTower Capital, an innovator in connecting blockchain markets globally, is partnering with Securitize, the leader in digital assets securities, to launch the BridgeTower Global Platform offering for Permissioned Markets. BridgeTower is also launching a Staked Digital Asset Security (SDAS) that will run in an Avalanche subnet .

BridgeTower is partnering with Securitize, its digital transfer agent, to offer its products through a seamless user interface. Investors simply need to create a Securitize iD, in which their identity is verified consistent with U.S. regulatory standards. They can then invest easily in opportunities across the BridgeTower ecosystem, as well as Securitize’s own offerings, including shares in private companies and institutional grade funds.

Transactions will utilize smart contracts and regulated custodians will provide transparency around asset collateralization using Chainlink Proof of Reserve, the market-leading oracle solution for auditing on-chain and off-chain reserves. Using Chainlink Proof of Reserve to verify the collateral of wrapped tokens across the multi-chain ecosystem, BridgeTower’s Permissioned Markets will unlock asset liquidity across many of the world’s most significant blockchains.

BridgeTower’s Permissioned markets will include DeFi financial products such as customized blockchain staking opportunities, token swaps and NFT development with arts, entertainment, and sporting ventures to provide seamless, institutionally compliant products.

With more than 5,000 of its own Staking Nodes, BridgeTower utilizes renewable energy to reduce the carbon footprint. Already a leading proof-of-stake infrastructure provider for leading Layer 1 blockchains and Web 3.0 companies, BridgeTower has built its fast-growing foundational staking and DeFi business through partnerships and investments over the past few years.

“We are bridging the value of innovative blockchain staking and DeFi products seamlessly to institutional investors,” said BridgeTower CEO Cory Pugh. “We have worked tirelessly to bring innovation and regulated processes by using our staking and DeFi products in Permissioned Markets to create a compliant gateway for institutions to participate in the evolving blockchain opportunity.”

“There is significant institutional demand to participate in DeFi opportunities, but the lack of safe places to participate has kept institutions on the sidelines. Now that Securitize is offering permissioned DeFi through on-chain attestations, as well as through our partnership with Avalanche to build a permissioned subnet, the doors to regulated DeFi have opened,” said Jamie Finn, president, and co-founder of Securitize. “The globally integrated platform BridgeTower has created will enable more institutions to enter the market confidently.”

AVAX STAKED DIGITAL ASSET SECURITY TO LAUNCH

"Avalanche has rapidly become the preferred destination for institutions to access the innovation emerging from decentralized finance and contribute their own expertise in creating products and ecosystems of value on-chain. I'm excited to see BridgeTower and Securitize expanding their involvement in the Avalanche community and building institutional-grade applications," said John Nahas, VP of Business Development at Ava Labs.

BridgeTower’s most recent product innovation is a Staked Digital Asset Security. The new security will receive staking rewards, and after one year’s hold time can be traded in the Permissioned Market. The AVAX Staking Security token will represent staked AVAX utilizing Smart Contracts, to mint staked utility tokens on the Avalanche Chain and run across a subnet. This will create a single digital asset security designed for institutional investors capable of administering KYC, whitelisting, cap table management and reporting. BridgeTower will launch additional products later this year.

The Digital Staking Asset AVAX Security will also be offered on the Securitized Markets Alternative Trading System making it available to a wide range of accredited investors. Currently, there are more than 400,000 investors participating in Securitize Markets. Eventually, it is expected that the AVAX Staked Digital Asset Security, and other Institutional-grade staking securities will also be offered on Layer 1, Web 3.0, and eventually other exchanges.

“We believe this product is unique, as a security, and will be attractive to institutional investors who are looking for a regulated, global security to participate in the dramatically expanding blockchain proof-of-stake market,” Pugh added. “We are thrilled to partner with Securitize and Avalanche and for the expertise they bring as industry leaders in their respective areas.”

About BridgeTower

BridgeTower Capital has developed a global platform to uniquely bring products to its own permissioned markets to seamlessly enable an institutional gateway to staking, DeFi, NFT and Web 3.0 entities. BridgeTower operates more than 5,000 of its own staking nodes and owns servers utilizing 100 percent renewable energy. Significant portions of returns from these products are reinvested to continually grow BridgeTower’s infrastructure and assets. BridgeTower is a global company based in Singapore with operating entities in Switzerland and the United States allowing it to compliantly address many of the most important jurisdictions in the global economy. Learn more at http://www.bridgetowercapital.com .

About Securitize

Securitize is a digital asset securities firm with a mission to provide stakeholders access to invest in and trade alternative investments, and for companies to raise capital, manage shareholders, and offer shareholders potential liquidity. Securitize has pioneered a fully digital, end-to-end platform for issuing, managing, and trading digital asset securities, consistent with the existing U.S. regulatory framework, with over 1.2 million investor accounts and 3,000 businesses connected. Securitize is comprised of Securitize, Inc. and its subsidiaries Securitize, LLC (an SEC-registered transfer agent), Securitize Capital, LLC, Securitize Markets, LLC (an SEC-registered broker-dealer, member of FINRA and SIPC , and operator of the company’s alternative trading system), and Pacific Stock Transfer. Learn more at http://www.securitize.io .

About Avalanche

Avalanche is the fastest smart contracts platform in the blockchain industry, as measured by time-to-finality. Avalanche is blazingly fast, low cost, and eco-friendly. Any smart contract-enabled application can outperform its competition by deploying on Avalanche. Don’t believe it? Try an app on Avalanche today.

Securitize Disclosures

Securities offered on the Securitize Markets ATS have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Assets listed herein, such as digital assets or tokens using blockchain, are speculative, involve a high degree of risk, are generally illiquid, may have no value, have limited regulatory certainty, are subject to potential market manipulation risks and may expose investors to loss of principal. Blockchain investing involves a degree of risk that can be different from traditional markets. These risks include, but are not limited to, risk of regulatory uncertainty, market adoption, market manipulation, market exiting, price volatility and security risk. Investments in private placements, start-up investments in particular, are also speculative and involve a high degree of risk. Investors must be able to afford the loss of their entire investment. Eligibility to buy and sell securities on the Securitize Markets ATS is determined by Securitize Markets in its sole discretion. Offers to sell, or the solicitations of offers to buy any security can only be made through official offering documents that contain important information about risks, fees and expenses associated with the applicable securities available for trading on the Securitize Markets ATS. Investors should conduct their own due diligence, and are encouraged to consult with a financial advisor, attorney, accountant, tax advisors, and any other professional that can help you to understand and assess the risks associated with any investment opportunity. Past performance is not indicative of future results. There is no guarantee that a diversified portfolio will enhance overall returns, outperform a non-diversified portfolio, or prevent against loss

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release

Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release

Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –

The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release

New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &

Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release

Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste

The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release

Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye